TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: reduction in reported angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in the frequency of ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary SP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of cervical esophageal wall opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intake of fruit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MPJ extension ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flexor hallucis strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of time hemoglobin within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in MT after Nd:YAG laser capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute mean reductions in lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in total score on the CAPS‐2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intrusive subscale score of the CAPS‐2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hyperarousal subscale score of the CAPS‐2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical infection
Endpoint domain: Adverse events/effects
Primary endpoint: Intention to screen for prostate cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correct identification of PSA test accuracy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported level of being informed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to new antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop-off detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for TIMI bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Net adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Median Time to Progression (TTP)
Endpoint domain: Mortality/survival
Primary endpoint: Mean daily blood glucose (BG) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tHcy concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined primary endpoint (death, mechanical ventilation or MI)
Endpoint domain: Mortality/survival
Primary endpoint: Intubation and mechanical ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the risk of multiple falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-day improvement in the pneumonia severity index risk rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early epidural failure
Endpoint domain: Adverse events/effects
Primary endpoint: Need for diazepam
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healing of corneal abrasions without complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of relapsing episodes
Endpoint domain: Mortality/survival
Primary endpoint: appropriate treatment received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score for pain and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical component of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of posttraumatic subtalar arthritis
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in inflammatory, non-inflammatory and total lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluator's global severity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic accuracy for cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensitivity in recognizing cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pneumonia vaccination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza/pneumonia ED visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in alveolar osteitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pHi at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak sacral pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean vertical augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: bone resorption percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Success rate of dogs distinguishing bladder cancer urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral hygiene efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alliance levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IVF outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first cry duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent preference visual analog scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression of visual field defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DDD of targeted antibiotic use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean QALYs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Zinc absorption from bread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Zinc absorption from porridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Zinc absorption from fortified porridge with zinc oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall DMQLS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HBV viral load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 month success rate of ocular deviations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postinjection blepharoptosis
Endpoint domain: Adverse events/effects
Primary endpoint: 0800 hours plasma cortisol suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: abnormally low 0800 hours cortisol values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Expression of autophagy-associated proteins (LC3-II and Beclin-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cell proliferation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cell viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevention of contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metformin oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topiramate oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure to pioglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subdomain esteem relative to physical condition and strength
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: body attractiveness subdomain esteem
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lumbar extensor strength gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking endurance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 min walk distance (6MW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colony forming efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transwell migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean time of resolution of cobblestone papillae, limbal edema, shield ulcer, SPK and relief of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walk time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperkalemia (HK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival benefit of eplerenone
Endpoint domain: Mortality/survival
Primary endpoint: adequate BSE performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychomotor task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime vigilance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: driving ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of MBF measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of low birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall leakage rate
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of radiation‐induced late rectal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life related to sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Quality of life related to cancer worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary nitrogen balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gut mucosal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agitation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jump height improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported use of allocated emollient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total sedentary time reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Domain-specific sedentary time reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVEF (Left ventricular ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: major or clinically relevant non-major bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Prolongation of safe apnea times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhibit SpO2 < 95% during apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol/drug-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in diacylglycerol (DAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ceramide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased dependence in ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: increased wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: absence of documented persistent atrial tachyarrhythmias relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CYP-mediated herb-drug interactions
Endpoint domain: Adverse events/effects
Primary endpoint: mean number of stools per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: general efficacy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: myocardial infarction rates
Endpoint domain: Adverse events/effects
Primary endpoint: Post-intubation PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean equilibrated protein catabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upper arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of chest pain episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of remission at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with an unfavorable response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMT Part B performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BBS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of central venous catheter insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of local haematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Basal ACTH plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: new-onset of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermediate DASH accordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saturated fat accordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASQoL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improvement in voiding parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: pelvic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone density loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in BCVA at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in CRT at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful extension of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shade matching quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving > 50% improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction score ≥ 5
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood pressure amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: blood pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: blood pressure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Overall efficacy judgement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teamwork
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Penetration Aspiration Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dual contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abstinence from sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of refractory ischemia or re-infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in CD11c+ cells in PP skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in CD68+ cells in PP skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Restoration of loricrin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reversal of plaque histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatocyte growth factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-specific mortality (DSM)
Endpoint domain: Mortality/survival
Primary endpoint: Distant metastasis (DM)
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical failure (BF)
Endpoint domain: Mortality/survival
Primary endpoint: success rate at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median induction-to-abortion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side effects (febrile episodes and chills/rigors)
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with sex life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global SUV uptake of 68Ga-DOTATOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global SUV uptake of [18F]FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in airway space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increases in bone marrow edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma ghrelin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of upper gastrointestinal bleeding (UGIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median TLUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aortic reservoir pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of ascitic fluid containing blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amylase levels in drained fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death by hemorrhagic shock
Endpoint domain: Mortality/survival
Primary endpoint: 30‐minute and 60‐minute responses to ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of patients failing to reach normal maximum cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endoscopic and histological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clearance rate of H pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Albuminuria reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma creatinine concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: viral shedding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in CD36 + MP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial component rotation amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about effectiveness of contraceptive methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status